ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2026
Uncovering hypothesis-generating associations between prescription drugs and digestive cancer risk: a case-control drug-wide association study (DWAS).
Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundPrescription drug use among older adults is more common than ever, yet traditional trials are not designed to assess long-term outcomes. Thus, the potential impact of widely used medications on cancer risk remains unclear. This is particularly a concern for digestive cancers for several reasons, most notably their key role in drug absorption and metabolism. We therefore leverage large-scale data to conduct a multi-stage study, aimed at identifying potential associations between oral prescription drugs and digestive cancer risk.
methodsWe used the Surveillance, Epidemiology and End Results (SEER)-Medicare data for a case-control drug-wide association study (DWAS), followed by targeted analyses to further address confounding. Subsequent analyses conducted include incorporation of additional adjustment for comorbidities, use of active comparators as well as propensity scores. Associations between prescription drugs and digestive cancer were assessed using adjusted odds ratios (OR), with significance assessed using Benjamini-Yekutieli (BY)-adjusted p-values.
resultsIn initial scan, 218 of 442 oral prescription drugs were associated with digestive cancer (BY-adjusted p<0.05). After our multi-stage targeted analyses, 38 drugs of interest (vs. their active comparators) remained associated with digestive cancer. Specifically, 10 drugs were positively associated (OR>1) and 28 were inversely associated (OR<1).
conclusionsOur study confirms some previously reported associations and identifies additional potential, novel associations between individual oral prescription drugs and digestive cancer that merit additional follow-up. IMPACT: These findings support the utility of our approach for hypothesis generation and warrant targeted confirmation in prospective studies as well as investigation of specific cancer types driving these associations.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.